| Description |
1 online resource (202 pages) |
| Contents |
Chapter 4: Monitoring AML Response Using "Difference from Normal" Flow CytometryIntroduction; Definition of Normal; Mutations Affect Phenotypic Expression; Specimen Composition and Quality; Lower Level of Detection; Performance Characteristics; Assay Validation; Direct Validation of [delta]N Post-HSCT; Correlative Validation of Response to Therapy; Indirect Validation to Monitoring Response to Therapy; MRD by Flow Cytometry Incorporated into Risk Stratification; References; Chapter 5: ML-DS: A Unique Condition for Measurable Residual Disease Detection; Introduction |
|
Intro; Contents; Contributors; Chapter 1: Introduction; History of DNA Sequencing; Next-Generation Sequencing Application; Roche 454 Pyrosequencing; Illumina (Solexa) Sequencers; Sequencing by Oligonucleotide Ligation and Detection (SOLiD); Ion Torrent; DNA Nanoball Sequencing (DNBS); Third-Generation Sequencing; Single-Molecule Real Time (SMRT); Helicos Sequencing; Next-Generation Sequencing by Electron Microscopy; Fourth-Generation Sequencing; Nanopore Sequencing; BioNano Genomics; Emerging Platforms: Single-Cell Sequencing (SCS); References |
|
Chapter 2: Minimal Residual Disease Testing in Acute Lymphoblastic Leukemia/LymphomaIntroduction; Minimal Residual Disease; Methods to Assess MRD; Flow Cytometry; Phenotypic Switch and Drug-Induced Immunophenotypic Modulation; Flow Cytometry Panels; Molecular PCR; Advantages and Disadvantages; Comparison of PCR and Flow Cytometry in Clinical Studies; Next-Generation Sequencing; NGS in T-ALL; NGS in B-ALL; Risk Stratification and the Threshold for MRD Detection; Does Therapeutic Intensification Overcome the Adverse Prognostic Effect of MRD?; Using MRD to Redefine Response |
|
MRD as a Surrogate Marker of ResponseSummary; References; Chapter 3: Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies; Introduction; RQ-PCR; BCR-ABL1; PML-RARA; CBF-AML (Core-Binding Factor AML); t(8; 21); RUNX1-RUNX1T1; Inv(16); MLL; WT1 Expression; BCL1 and BCL2 RQ-PCR; New Emerging and Patient-Specific; Flow Cytometric Cell Sorting (FACS); FACS Immunoglobulin (Ig) and T-Cell Receptor (TCR) Gene Rearrangements; FACS-FISH (Fluorescence In Situ Hybridization); NGS (Next-Generation Sequencing); AML; B- and T-Cell Malignancies; References |
|
Minimizing Treatment-Related Toxicity: Early Treatment AdvancesMultidimensional Flow Cytometry in ML-DS Treatment and Residual Disease Monitoring; Making Sense of the Somatic Mutation Landscapes: Leveraging Error-Corrected NGS; Conclusions and Future Outlook; References; Chapter 6: Advancements in Next-Generation Sequencing for Detecting Minimal Residual Disease; Introduction; Cancer Genetics; History of DNA Sequencing; Next-Generation Sequencing Application; Bioinformatics and NGS; Quality Assessment of NGS Libraries; Genome Alignment and Processing; Variant Detection and Annotation |
| Summary |
This volume provides a concise yet comprehensive overview of minimal residual disease (MRD) testing. The text reviews the history of MRD testing, MRD testing for acute lymphoblastic leukemia/lymphoma, molecular diagnostics for MRD analysis in hematopoietic malignancies, the use of "difference from normal" flow cytometry in monitoring AML response, ML-DS for measurable residual disease detection, and advancements in next generation sequencing for detecting MRD. Written by experts in the field, Minimal Residual Disease Testing: Current Innovations and Future Directions is a valuable resource for hematologists, oncologists, pathologists, and radiologists on the variety of technologies available to detect MRD and how best to integrate these platforms into clinical practice |
| Notes |
Variant Filtering and Association Analyses |
|
Includes index |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Diagnosis.
|
|
Molecular diagnosis.
|
|
Neoplasm, Residual -- diagnosis
|
|
Molecular Diagnostic Techniques -- methods
|
|
Flow Cytometry -- methods
|
|
High-Throughput Nucleotide Sequencing -- methods
|
|
Diagnosis
|
|
diagnosis.
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Diagnosis
|
|
Molecular diagnosis
|
| Form |
Electronic book
|
| Author |
Druley, Todd E
|
| LC no. |
2018957568 |
| ISBN |
9783319948270 |
|
331994827X |
|
